Join
Live feed
·
PRReleasevia Quantisnow
CG Oncology Inc. logo

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

ByQuantisnow·Wall Street's wire, on your screen.
CGON· CG Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGON (CG Oncology Inc.) and more on Quantisnow.